产品描述
| 溶解性 |
|
| 存贮条件 | 储存温度-20°C |
| 产品介绍 | Apremilast (CC-10004)是一种口服生物有效的PDE4和TNF-α抑制剂，IC50分别为74 nM和77 nM。 |
| 生化机理 | Apremilast, a novel small mol. inhibitor of PDE4. Apremilast has profound anti-inflammatory properties in animal models of inflammatory disease, as well as human chronic inflammatory diseases such as psoriasis and psoriatic arthritis. Apremilast blocks the synthesis of several pro-inflammatory cytokines and chemokines, such as tumor necrosis factor alpha, interleukin 23, CXCL9, and CXCL10 in multiple cell types. As this novel PDE4 inhibitor interferes with several key processes of inflammation, Apremilast may emerge as a promising new drug for the treatment of chronic inflammatory diseases such as those of the skin and the joints. |
| 别名 | (S)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮;CC-10004;ApreMilast;(S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide;ApreMilast,CC-10004 |
